Literature DB >> 26672118

Characterizing the Burden of Hepatitis C Infection Among Entrants to Pennsylvania State Prisons, 2004 to 2012.

Madeline K Mahowald1, Sarah Larney2, Nickolas D Zaller3, Nicholas Scharff4, Lynn E Taylor5, Curt G Beckwith5, Amanda Noska6, Josiah D Rich5, Timothy P Flanigan5.   

Abstract

Although hepatitis C (HCV) infection is common among prisoners, relatively few undergo evaluation for treatment. This study reports the prevalence of chronic infection and the genotype distribution among an incarcerated population. HCV antibody testing was provided to adults entering Pennsylvania prisons; confirmatory and genotype testing were offered to those eligible for treatment. Antibody prevalence among 101,727 individuals was 18.1%. Among 7,633 individuals who underwent confirmatory testing, 69.3% had detectable RNA. Among 3,247 individuals who underwent genotype testing, genotype 1 was the most common (76.6%). The rate of chronic infection after HCV exposure is similar to that reported in the community, as is genotype distribution. Correctional facilities provide access to a population with a high disease burden, creating a public health opportunity for evaluation and treatment.
© The Author(s) 2015.

Entities:  

Keywords:  chronic hepatitis C infection; correctional health; hepatitis C genotype distribution; prevalence

Mesh:

Substances:

Year:  2016        PMID: 26672118      PMCID: PMC4683408          DOI: 10.1177/1078345815618384

Source DB:  PubMed          Journal:  J Correct Health Care        ISSN: 1078-3458


  10 in total

1.  Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings.

Authors:  Sarah Larney; Madeline K Mahowald; Nicholas Scharff; Timothy P Flanigan; Curt G Beckwith; Nickolas D Zaller
Journal:  Am J Public Health       Date:  2014-04-17       Impact factor: 9.308

2.  Prevalence of hepatitis C in a German prison for young men in relation to country of birth.

Authors:  M F Meyer; H Wedemeyer; M Monazahian; J Dreesman; M P Manns; M Lehmann
Journal:  Epidemiol Infect       Date:  2006-07-07       Impact factor: 2.451

3.  Hepatitis C seroprevalence among prison inmates since 2001: still high but declining.

Authors:  Aiden K Varan; Daniel W Mercer; Matthew S Stein; Anne C Spaulding
Journal:  Public Health Rep       Date:  2014 Mar-Apr       Impact factor: 2.792

4.  Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C.

Authors:  Kara W Chew; Scott A Allen; Lynn E Taylor; Josiah D Rich; Edward Feller
Journal:  J Clin Gastroenterol       Date:  2009-08       Impact factor: 3.062

5.  The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010.

Authors:  Ivo Ditah; Fausta Ditah; Pardha Devaki; Oforbuike Ewelukwa; Chobufo Ditah; Basile Njei; Henry N Luma; Michael Charlton
Journal:  J Hepatol       Date:  2013-11-27       Impact factor: 25.083

Review 6.  Current and future therapies for hepatitis C virus infection.

Authors:  T Jake Liang; Marc G Ghany
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245

7.  Treatment of chronic hepatitis C in a state correctional facility.

Authors:  Scott A Allen; Anne C Spaulding; Albert M Osei; Lynn E Taylor; Asya M Cabral; Josiah D Rich
Journal:  Ann Intern Med       Date:  2003-02-04       Impact factor: 25.391

Review 8.  Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis.

Authors:  Sarah Larney; Hannah Kopinski; Curt G Beckwith; Nickolas D Zaller; Don Des Jarlais; Holly Hagan; Josiah D Rich; Brenda J van den Bergh; Louisa Degenhardt
Journal:  Hepatology       Date:  2013-08-06       Impact factor: 17.425

9.  Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.

Authors:  Natasha K Martin; Matthew Hickman; Sharon J Hutchinson; David J Goldberg; Peter Vickerman
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

10.  Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

Authors:  Kris V Kowdley; Eric Lawitz; Fred Poordad; Daniel E Cohen; David R Nelson; Stefan Zeuzem; Gregory T Everson; Paul Kwo; Graham R Foster; Mark S Sulkowski; Wangang Xie; Tami Pilot-Matias; George Liossis; Lois Larsen; Amit Khatri; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

  10 in total
  5 in total

Review 1.  Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.

Authors:  Megan G Hofmeister; Elizabeth M Rosenthal; Laurie K Barker; Eli S Rosenberg; Meredith A Barranco; Eric W Hall; Brian R Edlin; Jonathan Mermin; John W Ward; A Blythe Ryerson
Journal:  Hepatology       Date:  2018-11-06       Impact factor: 17.425

2.  Performance of Risk-Based and Birth-Cohort Strategies for Identifying Hepatitis C Virus Infection Among People Entering Prison, Wisconsin, 2014.

Authors:  Lauren J Stockman; James Greer; Ryan Holzmacher; Beth Dittmann; Scott A Hoftiezer; Lori E Alsum; Audrey Prieve; Ryan P Westergaard; Sheila M Guilfoyle; James M Vergeront
Journal:  Public Health Rep       Date:  2016 Jul-Aug       Impact factor: 2.792

3.  "I'm not gonna be able to do anything about it, then what's the point?": A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail.

Authors:  Alysse G Wurcel; Jessica Reyes; Julia Zubiago; Peter J Koutoujian; Deirdre Burke; Tamsin A Knox; Thomas Concannon; Stephenie C Lemon; John B Wong; Karen M Freund; Curt G Beckwith; Amy M LeClair
Journal:  PLoS One       Date:  2021-05-26       Impact factor: 3.240

4.  The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017.

Authors:  Desmond Crowley; John S Lambert; Graham Betts-Symonds; Walter Cullen; Mary Keevans; Enda Kelly; Eamon Laird; Tina McHugh; Susan McKiernan; Sarah Jayne Miggin; Carol Murphy; Ross Murtagh; Deirdre O'Reilly; Ciara Tobin; Marie Claire Van Hout
Journal:  Euro Surveill       Date:  2019-04

5.  Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners.

Authors:  Desmond Crowley; Ross Murtagh; Walter Cullen; Mary Keevans; Eamon Laird; Tina McHugh; Susan McKiernan; Sarah Jayne Miggin; Eileen O'Connor; Deirdre O'Reilly; Graham Betts-Symonds; Ciara Tobin; Marie Claire Van Hout; John S Lambert
Journal:  Harm Reduct J       Date:  2019-07-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.